Home > Insider Trading > Filing (0000950103-20-015724)

Filing Details

Accession Number:: 0000950103-20-015724
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-08-12 21:06:09
Reporting Period:: 2020-08-10

Accepted Time:: 2020-08-12 21:06:09
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1522860	Acutus Medical Inc.	AFIB	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1055951	Orbimed Advisors Llc	601 Lexington Avenue 54Th Floor New York NY 10022	Yes	No	Yes	No
1502240	Orbimed Capital Gp Iv Llc	601 Lexington Avenue, 54Th Floor New York NY 10022	Yes	No	Yes	No
1767936	Orbimed Rof Ii Llc	601 Lexington Ave., 54Th Floor New York NY 10022	Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-08-10	373,500	$18.00	373,500	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2020-08-10	41,500	$18.00	41,500	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2020-08-10	3,784,240	$0.00	4,157,740	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2020-08-10	1,278,718	$0.00	1,320,218	No	4	C	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Convertible Preferred Stock	Disposition	2020-08-10	872,302	$0.00	872,302	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2020-08-10	673,123	$0.00	673,123	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2020-08-10	647,582	$0.00	647,582	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2020-08-10	899,985	$0.00	899,985	$0.00
Common Stock	Series D Convertible Preferred Stock	Disposition	2020-08-10	389,116	$0.00	389,116	$0.00
Common Stock	Series D Convertible Preferred Stock	Disposition	2020-08-10	1,202,117	$0.00	1,202,117	$0.00
Common Stock	Series D Convertible Preferred Stock	Disposition	2020-08-10	378,733	$0.00	378,733	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

These securities are held of record by OrbiMed Private Investments IV, LP ("OPI IV"). OrbiMed Capital GP IV LLC ("GP IV") is the general partner of OPI IV. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IV. By virtue of such relationships, GP IV and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI IV and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI IV.
These securities are held of record by OrbiMed Royalty Opportunities II, LP ("ORO II"). OrbiMed ROF II LLC ("ROF II") is the general partner of ORO II. OrbiMed Advisors is the managing member of ROF II. By virtue of such relationships, ROF II andOrbiMed Advisors may be deemed to have voting and investment power over the securities held by ORO II and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through amanagement committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by ORO II.
Each of GP IV, ROF II, and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, currently David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors.
Each of the Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, and Series D Convertible Preferred Stock is convertible into the Issuer's Common Stock on a one-for-one basis for no additional consideration and has no expiration date.